Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Glucuronide prodrug strategies may enhance target specificity and reduce the toxicity of PARP inhibitors, but no clinical evaluation has been performed. We evaluated TSL-1502, a novel glucuronide prodrug of a PARP inhibitor, in a randomized, open-label, phase 2 study at 28 sites in China (NCT05420779). Eligible patients were women aged 18–75 years with HER2-negative locally advanced or metastatic breast cancer and germline BRCA mutations.
Abstract Objective: Poly (ADP-ribose) polymerase (PARP) inhibitors, based on synthetic lethality, have demonstrated significant efficacy in tumors with homologous recombination repair (HRR) deficiencies but are limited by severe hematological toxicities. TSL-1502 is a glucuronide prodrug of a novel oral small-molecule PARP inhibitor that releases its active metabolite, TSL-1502M, specifically in tumor tissues.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.